Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT) Meeting Abstract


Authors: Kewalramani, T.; Zelenetz, A.; Bertino, J.; Donnelly, G.; Hedrick, E.; Noy, A.; O'connor, O.; Portlock, C.; Straus, D.; Yahalom, J.; Gencarelli, A.; Remy, D.; Qin, J.; Nimer, S.; Moskowitz, C.
Abstract Title: Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)
Meeting Title: 43rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 98
Issue: 11 Pt. 1
Meeting Dates: 2001 Dec 7-11
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2001-11-16
Start Page: 346a
Language: English
ACCESSION: WOS:000172134101463
PROVIDER: wos
PUBMED: 11727739
Notes: Meeting Abstract:1459 -- Source: Wos
MSK Authors
  1. Joachim Yahalom
    407 Yahalom
  2. Carol Portlock
    181 Portlock
  3. Craig Moskowitz
    375 Moskowitz
  4. Ariela Noy
    208 Noy
  5. Eric E Hedrick
    16 Hedrick
  6. Joseph Bertino
    270 Bertino
  7. Jing Qin
    86 Qin
  8. Andrew D Zelenetz
    556 Zelenetz
  9. Stephen D Nimer
    345 Nimer
  10. David J Straus
    213 Straus
  11. Daphne C Remy
    1 Remy